食管癌组织miR-133表达对其癌细胞生长的影响

doi:10.3969/j.issn.1671-7171.2021.01.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1485 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of miR-133 expression on the growth of esophageal cancer cells.【Methods】The expression of miR-133 in esophageal carcinoma was detected by RT-PCR. miR-133 mimics, anti-mir-133 and their corresponding controls were transfected into esophageal cancer cells by Lipofectamine 2000. RT-PCR was used to detect the expression of miR-133, MTT was used to detect the cell proliferation, and Western blot was used to detect the expression of EGFR protein.【Results】 The relative expression of miR-133 in esophageal carcinoma tissues (0.33±0.08) was significantly lower than that in adjacent normal tissues (1.15±0.18). Overexpression of miR-133 significantly inhibited the growth of esophageal cancer cells, while down-regulation of miR-133 significantly enhanced the growth of tumor cells. Meanwhile, overexpression of miR-133 inhibited the expression of EGFR mRNA and protein, and down-regulation of miR-133 significantly enhanced the expression of EGFR mRNA and protein. Overexpression of EGFR reverses the inhibitory effect of miR-133 on the growth of esophageal cancer cells.【Conclusion】 miR-133 inhibits the growth of esophageal cancer cells by regulating the expression of EGFR.

Key words： Esophageal Neoplasms/PA MicroRNAs Gene Expression Regulation Neoplastic Cell Proliferation

Received: 04 December 2020

PACS:

R735.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.01.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I1/64

[1] Siersema PD.Esophageal cancer[J].Gastroenterol Clin North Am,2008,37(4):943-964.
[2] Oh SJ, Han S, Lee W,et al. Emerging immunotherapy for the treatment of esophageal cancer[J].Expert Opin Investig Drugs,2016,25(6):667-677.
[3] Rupaimoole R, Slack FJ.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J].Nat Rev Drug Discov,2017,16(3):203-222.
[4] Lee YS, Dutta A.MicroRNAs in cancer[J].Annu Rev Pathol,2009,4:199-227.
[5] Calin GA, Croce CM.MicroRNA signatures in human cancers[J].Nat Rev Cancer,2006,6(11):857-866.
[6] Jansson MD, Lund AH.MicroRNA and cancer[J].Mol Oncol,2012,6(6):590-610.
[7] Paliouras AR, Monteverde T, Garofalo M.Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy[J].Cancer Lett,2018,421:152-160.
[8] Mishra S, Yadav T, Rani V.Exploring miRNA based approaches in cancer diagnostics and therapeutics[J].Crit Rev Oncol Hematol,2016,98:12-23.
[9] Zomorrod MS, Kouhkan F, Soleimani M,et al. Overexpression of miR-133 decrease primary endothelial cells proliferation and migration via FGFR1 targeting[J].Exp Cell Res,2018,369(1):11-16.
[10] Zhou Y, Wu D, Tao J,et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer[J].Scand J Urol,2013,47(5):423-432.
[11] Tao J, Wu D, Xu B,et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor[J].Oncol Rep,2012,27(6):1967-1975.
[12] Lu TX, Rothenberg ME.MicroRNA[J].J Allergy Clin Immunol,2018,141(4):1202-1207.
[13] Krol J, Loedige I, Filipowicz W.The widespread regulation of microRNA biogenesis, function and decay[J].Nat Rev Genet,2010,11(9):597-610.
[14] Bushati N, Cohen SM. microRNA functions[J].Annu Rev Cell Dev Biol,2007,23:175-205.
[15] Dragomir M.Using microRNA networks to understand cancer[J].Int J Mol Sci,2018,19(7):1871.
[16] Yang W, Han Y, Zhao X,et al. Advances in prognostic biomarkers for esophageal cancer[J].Expert Rev Mol Diagn,2019,19(2):109-119.
[17] Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer[J].Med Sci Monit,2012,18(3):RA22-RA30.
[18] Li B, Xu WW, Han L,et al. MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF[J].Oncogene,2017,36(28):3986-4000.
[19] Li N, Zhou H, Tang Q. miR-133: A Suppressor of Cardiac Remodeling?[J].Front Pharmacol,2018,9:903.
[20] Chen JF, Mandel EM, Thomson JM,et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation[J].Nat Genet,2006,38(2):228-233.
[21] Liu Y, Liang Y, Zhang JF,et al. MicroRNA-133 mediates cardiac diseases: mechanisms and clinical implications[J].Exp Cell Res,2017,354(2):65-70.
[22] Cheng Z, Liu F, Wang G,et al. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer[J].Cell Signal,2014,26(12):2667-2673.
[23] Liu Y, Han L, Bai Y,et al. Down-regulation of MicroRNA-133 predicts poor overall survival and regulates the growth and invasive abilities in glioma[J].Artif Cells Nanomed Biotechnol,2018,46(1):206-210.
[24] Kawakami K, Enokida H, Chiyomaru T,et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma[J].Eur J Cancer,2012,48(6):827-836.
[25] Wang Y, Li J, Chen H,et al. Down-regulation of miR-133a as a poor prognosticator in non-small cell lung cancer[J].Gene,2016,591(2):333-337.
[26] Lin WC, Chen LH, Hsieh YC,et al. miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2[J].Carcinogenesis,2019,40(7):883-892.
[27] Duhachek-Muggy S, Zolkiewska A.ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer[J].BMC Cancer,2015,15:93.
[28] Kaplan M, Narasimhan S, de Heus C,et al. EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR[J].Cell,2016,167(5):1241-1251.
[29] Nicholson RI, Gee JM, Harper ME.EGFR and cancer prognosis[J].Eur J Cancer,2001,37(Suppl 4):S9-S15.
[30] Chong CR, Jänne PA.The quest to overcome resistance to EGFR-targeted therapies in cancer[J].Nat Med,2013,19(11):1389-1400.
[31] Yarden Y.The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities[J].Eur J Cancer,2001,37(Suppl 4):S3-S8.
[32] Song S, Honjo S, Jin J,et al. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer[J].Clin Cancer Res,2015,21(11):2580-2590.
[33] Yoshioka M, Ohashi S, Ida T,et al. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells[J].J Exp Clin Cancer Res,2017,36(1):101.
[34] Sato F, Kubota Y, Natsuizaka M,et al. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition[J].Cancer Biol Ther,2015,16(6):933-940.
[35] Liu S, Chen J, Zhang T,et al. MicroRNA-133 inhibits the growth and metastasis of the human lung cancer cells by targeting epidermal growth factor receptor[J].J BUON,2019,24(3):929-935.